In the buyout, Barclays Private Equity has acquired a controlling stake in the company while existing investors ING Parcom Private Equity, CM-CIC Investissement and Picardie Investissement, are reinvesting in Unither and will act as minority shareholders.
The restructuring of the company’s share capital, whose completion is still subject to standard regulatory clearances, is part of a strategy to pursue organic and external growth over the next five years.
Led by President Eric Goupil, Unither Pharmaceuticals is currently a manufacturer of dosage forms (products ready for customer use) for European pharmaceutical laboratories, and generic products (particularly eyewashes, saline solutions and anti-asthma drugs in sterile single-dose units and stick-packs).
The company has four industrial sites and an R&D centre. It currently employs more than 850 people.